Motif Bio to Present Iclaprim Data at ESCMID/ASM Conference

(Source: MarketWatch) Clinical and microbiological data indicate that iclaprim has a targeted … from two Phase 3 trials (REVIVE-1 and REVIVE-2), a New Drug Application (NDA) was …